CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse

Virus Research

Volumn 217, Issue , 2016, Pages 125-132

  Zhu, Wei ^a   Xie, Kun ^a   Xu, Yuanjian ^a   Wang, Le ^a   Chen, Kaiming ^a   Zhang, Longzhen ^a   Fang, Jianmin ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

CccDNA; CRISPR Cas9; HBV; Hydrodynamics

Indexed keywords

CRISPR ASSOCIATED PROTEIN; HEPATITIS B CORE ANTIBODY; ANTIVIRUS AGENT; BACTERIAL PROTEIN; CAS9 ENDONUCLEASE STREPTOCOCCUS PYOGENES; CIRCULAR DNA; ENDONUCLEASE; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRISPR CAS SYSTEM; GENOTYPE; HEPATITIS B VIRUS; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; HEPATITIS B; TRANSGENIC MOUSE; TUMOR CELL LINE; VIRUS GENOME;

ANIMALS; ANTIVIRAL AGENTS; BACTERIAL PROTEINS; CELL LINE, TUMOR; CRISPR-CAS SYSTEMS; DNA, CIRCULAR; DNA, VIRAL; DRUG DELIVERY SYSTEMS; ENDONUCLEASES; GENOME, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MICE; MICE, TRANSGENIC;

EID: 84962685045     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2016.04.003     Document Type: Article

References (37)

1. Barrangou R., Fremaux C., Deveau H., Richards M., Boyaval P., Moineau S., et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007, 315:1709-1712.
2. Belloni L., Pollicino T., De Nicola F., Guerrieri F., Raffa G., Fanciulli M., et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:19975-19979.
3. Belloni L., Allweiss L., Guerrieri F., Pediconi N., Volz T., Pollicino T. IFN-a inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J. Clin. Invest. 2012, 122:529-537.
4. Bloom K., Ely A., Mussolino C., Cathomen T., Arbuthnot P. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol. Ther. 2013, 21:1889-1897.
5. Chen J., Zhang W., Lin J., Wang F., Wu M., Chen C., et al. An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol. Ther. 2014, 22:303-311.
6. Cho S.W., Kim S., Kim J.M., Kim J.S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 2013, 31:230-232.
7. Christman J.K., Gerber M., Price P.M., Flordellis C., Edelman J., Acs G. Amplification of expression of hepatitis B surface antigen in 3T3 cells cotransfected with a dominant-acting gene and cloned viral DNA. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:1815-1819.
8. Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339:819-823.
9. Cradick T.J., Keck K., Bradshaw S., Jamieson A.C., McCaffrey A.P. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol. Ther. 2010, 18:947-954.
10. Dandri M., Burda M.R., Will H., Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 2000, 32:139-146.
11. Dong C., Qu L., Wang H., Wei L., Dong Y., Xiong S. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res. 2015, 118:110-117.
12. Gaj T., Gersbach C.A., Barbas C.F. ZFN, TALEN, and CRISPR/Cas -based methods for genome engineering. Trends Biotechnol. 2013, 31:397-405.
13. Gao W., Hu J. Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J. Virol. 2007, 81:6164-6174.
14. Hayer J., Jadeau F., Deléage G., Kay A., Zoulim F., Combet C. HBVdb: a knowledge database for hepatitis B virus. Nucleic Acids Res. 2013, 41:566-570.
15. Huang L.R., Wu H.L., Chen P.J., Chen D.S. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17862-17867.
16. Lai C.L., Ching C.K., Tung A.K., Li E., Young J., Hill A., et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997, 25:241-244.
17. Le D.Y., Blanchet M., Sureau C. The pre-s1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent. J. Virol. 2009, 83:12443-12451.
18. Lin S.R., Yang H.C., Kuo Y.T., Liu C.J., Yang T.Y., Sung K.C., et al. The crispr/cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol. Ther. Nucleic Acids 2014, 19(3):e186.
19. Liu X., Hao R., Chen S., Guo D., Chen Y. Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome. J. Gen. Virol. 2015, 96:2252-2261.
20. Lucifora J., Arzberger S., Durantel D., Belloni L., Strubin M., Levrero M., et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J. Hepatol. 2011, 55:996-1003.
21. Lucifora J., Xia Y., Reisinger F., Zhang K., Stadler D., Cheng X., et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014, 343:1221-1228.
22. Pollicino T., Raffa G., Santantonio T., Gaeta G.B., Iannello G., Alibrandi A., et al. Replicative and transcriptional activities of hepatitis b virus in patients coinfected with hepatitis B and hepatitis delta viruses. J. Virol. 2011, 1:432-439.
23. Quasdorff M., Protzer U. Control of hepatitis B virus at the level of transcription. J. Viral Hepat. 2010, 17:527-536.
24. Ramanan V., Shlomai A., Cox D.B., Schwartz R.E., Michailidis E., Bhatta A., et al. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci. Rep. 2015, 5:10833-10842.
25. Ren J., Wang L., Chen Z., Ma Z.M., Zhu H.G., Yang D.L., et al. Gene expression profile of transgenic mouse kidney reveals pathogenesis of hepatitis B virus associated nephropathy. J. Med. Virol. 2006, 78:551-560.
26. Sander J.D., Joung J.K. CRISPR-cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 2014, 32:347-355.
27. Schaefer S. Hepatitis B virus: significance of genotypes. J. Viral Hepat. 2005, 12:111-124.
28. Seeger C., Sohn J.A. Targeting hepatitis B virus with CRISPR/Cas9. Mol. Ther. Nucleic Acids 2014, 3:e216.
29. Sung J.J., Wong M.L., Bowden S., Liew C.T., Hui A.Y., Wong V.W., et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005, 128:1890-1897.
30. Sureau C., Salisse J. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology 2013, 57:985-994.
31. Trepo C., Chan H.L., Lok A. Hepatitis B virus infection. Lancet 2014, 384:2053-2063.
32. Werle-Lapostolle B., Bowden S., Locarnini S., Wursthorn K., Petersen J., Lau G., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004, 126:1750-1758.
33. Yan H., Zhong G., Xu G., He W., Jing Z., Gao Z., et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012, 3. 10.7554/eLife.00049.
34. Yang H.C., Kao H.J. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. Emerging Microbes Infect. 2014, 3:e64.
35. Yang W., Summers J. Illegitimate replication of linear hepadnavirus DNA through nonhomologous recombination. J. Virol. 1995, 69:4029-4036.
36. Yang W., Summers J. Infection of ducklings with virus particles containing linear double-stranded duck hepatitis B virus DNA: illegitimate replication and reversion. J. Virol. 1998, 72:8710-8717.
37. Zhu C., Gupta A., Hall V.L., Rayla A.L., Christensen R.G., Dake B., et al. Using defined finger-finger interfaces as units of assembly for constructing zinc-finger nucleases. Nucleic Acids Res. 2013, 41:2455-2465.